- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - AZN: Year-to-date and Q3 2020 results
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Atacand to be divested in more than 70 countries
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Enhertu US Priority Review in gastric cancer
AnnouncementREG - AstraZeneca PLC - Forxiga CV outcomes benefit approved in China
AnnouncementREG - AstraZeneca PLC - Tagrisso adjuvant lung cancer US Priority Review
AnnouncementREG - AstraZeneca PLC - Forxiga HF receives positive CHMP opinion
AnnouncementREG - AstraZeneca PLC - Trixeo Aerosphere receives positive CHMP opinion
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - COVID-19 antibodies advance and get US funding
AnnouncementREG - Circassia Group Plc AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Farxiga granted US BTD in chronic kidney disease
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Lynparza EU recommendation in prostate cancer
AnnouncementREG - AstraZeneca PLC - Tagrisso reduced early lung cancer brain recurrenc
AnnouncementREG - AstraZeneca PLC - Lynparza EU recommendation in ovarian cancer
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
Announcement